These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16436489)

  • 1. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
    Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M
    Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
    Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
    Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Alten R; Burmester G; Gromnica-Ihle E; Haibel H; Schewe S; Schneider M; Sörensen H; Zeidler H; Visvanathan S; Sieper J; Braun J
    J Rheumatol; 2007 Mar; 34(3):510-5. PubMed ID: 17299842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab treatment in ankylosing spondylitis: an observational study.
    Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
    Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
    Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis].
    Vinagre F; Santos MJ; Silva JC
    Acta Reumatol Port; 2007; 32(3):271-3. PubMed ID: 17940497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis.
    Chu Miow Lin D; Mulleman D; Azzopardi N; Griffoul-Espitalier I; Valat JP; Paintaud G; Goupille P
    Scand J Rheumatol; 2010; 39(1):97-8. PubMed ID: 20132079
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
    Keeling S; Oswald A; Russell AS; Maksymowych WP
    J Rheumatol; 2006 Mar; 33(3):558-61. PubMed ID: 16463437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
    Baraliakos X; Listing J; Fritz C; Haibel H; Alten R; Burmester GR; Krause A; Schewe S; Schneider M; Sörensen H; Schmidt R; Sieper J; Braun J
    Rheumatology (Oxford); 2011 Sep; 50(9):1690-9. PubMed ID: 21672969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of infliximab in academic rheumatology practice: an audit of early clinical experience.
    Fitzcharles MA; Clayton D; Ménard HA
    J Rheumatol; 2002 Dec; 29(12):2525-30. PubMed ID: 12465146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
    Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
    Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.